Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 228

1.

Management of allergy transfer upon solid organ transplantation.

Muller YD, Vionnet J, Beyeler F, Eigenmann P, Caubet JC, Villard J, Berney T, Scherer K, Spertini F, Fricker MP, Lang C, Schmid-Grendelmeier P, Benden C, Roux Lombard P, Aubert V, Immer F, Pascual M, Harr T; Swiss Transplant Cohort Study.

Am J Transplant. 2019 Sep 18. doi: 10.1111/ajt.15601. [Epub ahead of print]

PMID:
31535461
2.

Novel Nanofluidic IgE Assay versus a Reference Method: A Real-World Comparison.

Roethlisberger S, Karoui O, Mapelli D, Audran R, Aubert V, Girard LD, Rebeaud F, Leimgruber A, Buss G, Duc J, Langner-Viviani F, Maerki I, Spertini F.

Int Arch Allergy Immunol. 2019;180(1):28-36. doi: 10.1159/000500830. Epub 2019 Jun 12.

PMID:
31189157
3.

The adjuvant GLA-SE promotes human Tfh cell expansion and emergence of public TCRβ clonotypes.

Hill DL, Pierson W, Bolland DJ, Mkindi C, Carr EJ, Wang J, Houard S, Wingett SW, Audran R, Wallin EF, Jongo SA, Kamaka K, Zand M, Spertini F, Daubenberger C, Corcoran AE, Linterman MA.

J Exp Med. 2019 Aug 5;216(8):1857-1873. doi: 10.1084/jem.20190301. Epub 2019 Jun 7.

4.

Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance.

Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, Shabafrouz K, Ribi C, Cairoli A, Guex-Crosier Y, Kuntzer T, Michielin O, Peters S, Coukos G, Spertini F, Thompson JA, Obeid M.

Nat Rev Clin Oncol. 2019 Sep;16(9):563-580. doi: 10.1038/s41571-019-0218-0. Review.

PMID:
31092901
5.

Davantage de silence.

Seebach J, Spertini F.

Rev Med Suisse. 2019 Apr 3;15(645):703-704. French. No abstract available.

PMID:
30942966
6.

[Risk of treatment failure and therapeutic novelties in asthma].

Horisberger A, Mahdi Aljedani R, Spertini F, Ribi C.

Rev Med Suisse. 2019 Jan 9;15(N° 632-633):23-26. French.

PMID:
30629362
7.

[Where are we with oral immunotherapy for food allergy ?]

Borgeat Kaeser A, Moi L, Spertini F.

Rev Med Suisse. 2019 Jan 9;15(N° 632-633):20-22. French.

PMID:
30629361
8.

New therapeutic perspectives to manage refractory immune checkpoint-related toxicities.

Martins F, Sykiotis GP, Maillard M, Fraga M, Ribi C, Kuntzer T, Michielin O, Peters S, Coukos G, Spertini F, Thompson JA, Obeid M.

Lancet Oncol. 2019 Jan;20(1):e54-e64. doi: 10.1016/S1470-2045(18)30828-3.

PMID:
30614479
9.

A severe case of refractory esophageal stenosis induced by nivolumab and responding to tocilizumab therapy.

Horisberger A, La Rosa S, Zurcher JP, Zimmermann S, Spertini F, Coukos G, Obeid M.

J Immunother Cancer. 2018 Dec 27;6(1):156. doi: 10.1186/s40425-018-0481-0.

10.

Supplemental parenteral nutrition improves immunity with unchanged carbohydrate and protein metabolism in critically ill patients: The SPN2 randomized tracer study.

Berger MM, Pantet O, Jacquelin-Ravel N, Charrière M, Schmidt S, Becce F, Audran R, Spertini F, Tappy L, Pichard C.

Clin Nutr. 2019 Oct;38(5):2408-2416. doi: 10.1016/j.clnu.2018.10.023. Epub 2018 Nov 5.

PMID:
30448193
11.

Prospective evaluation of the capillaroscopic skin ulcer risk index in systemic sclerosis patients in clinical practice: a longitudinal, multicentre study.

Walker UA, Jaeger VK, Bruppacher KM, Dobrota R, Arlettaz L, Banyai M, Beron J, Chizzolini C, Groechenig E, Mueller RB, Spertini F, Villiger PM, Distler O.

Arthritis Res Ther. 2018 Oct 25;20(1):239. doi: 10.1186/s13075-018-1733-6.

12.

The Candidate Blood-stage Malaria Vaccine P27A Induces a Robust Humoral Response in a Fast Track to the Field Phase 1 Trial in Exposed and Nonexposed Volunteers.

Steiner-Monard V, Kamaka K, Karoui O, Roethlisberger S, Audran R, Daubenberger C, Fayet-Mello A, Erdmann-Voisin A, Felger I, Geiger K, Govender L, Houard S, Huber E, Mayor C, Mkindi C, Portevin D, Rusch S, Schmidlin S, Tiendrebeogo RW, Theisen M, Thierry AC, Vallotton L, Corradin G, Leroy O, Abdulla S, Shekalaghe S, Genton B, Spertini F, Jongo SA.

Clin Infect Dis. 2019 Jan 18;68(3):466-474. doi: 10.1093/cid/ciy514.

PMID:
29945169
13.

Benefit of Bet v 1 contiguous overlapping peptide immunotherapy persists during first follow-up season.

Kettner A, DellaCorte G, de Blay F, Jacobsen L, Jutel M, Worm M, Charlon V, Simonsen K, Reymond C, Spertini F.

J Allergy Clin Immunol. 2018 Aug;142(2):678-680.e7. doi: 10.1016/j.jaci.2018.01.052. Epub 2018 Apr 17. No abstract available.

PMID:
29678749
14.

[Sublingual immunotherapy for the treatment of allergic rhinoconjonctivitis and asthma : a practical approach].

Ghosn J, Spertini F, Comte D.

Rev Med Suisse. 2018 Apr 4;14(601):735-739. French.

PMID:
29620296
15.

[Seasonal allergic rhinitis].

Salvadé I, Moi L, Ribi C, Spertini F.

Rev Med Suisse. 2018 Apr 4;14(601):726-730. French.

PMID:
29620294
16.

Nouvelles thérapeutiques et coûts de la médecine.

Spertini F, Seebach J.

Rev Med Suisse. 2018 Apr 4;14(601):723-724. French. No abstract available.

PMID:
29620293
17.

Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease.

Gabay C, Fautrel B, Rech J, Spertini F, Feist E, Kötter I, Hachulla E, Morel J, Schaeverbeke T, Hamidou MA, Martin T, Hellmich B, Lamprecht P, Schulze-Koops H, Courvoisier DS, Sleight A, Schiffrin EJ.

Ann Rheum Dis. 2018 Jun;77(6):840-847. doi: 10.1136/annrheumdis-2017-212608. Epub 2018 Feb 22.

18.

Sjögren's Disease Associated with Severe Retinal Vasculitis and/or Necrotizing Scleritis: Two Cases.

Lopez Baumann S, Borgeat Kaeser A, Valerio F, Spertini F, Guex-Crosier Y.

Klin Monbl Augenheilkd. 2018 Apr;235(4):480-482. doi: 10.1055/s-0043-123641. Epub 2018 Feb 16. No abstract available.

PMID:
29452446
19.

TBVAC2020: Advancing Tuberculosis Vaccines from Discovery to Clinical Development.

Kaufmann SHE, Dockrell HM, Drager N, Ho MM, McShane H, Neyrolles O, Ottenhoff THM, Patel B, Roordink D, Spertini F, Stenger S, Thole J, Verreck FAW, Williams A; TBVAC2020 Consortium.

Front Immunol. 2017 Oct 4;8:1203. doi: 10.3389/fimmu.2017.01203. eCollection 2017. Review.

20.

Successful therapy with mycophenolic acid in a membranous glomerulonephritis due to Kimura disease
.

Gaillard J, Rotman S, Girardet C, Spertini F.

Clin Nephrol. 2017 Oct;88(10):221-225. doi: 10.5414/CN109086.

PMID:
28853699
21.

[Food-dependent exercise-induced anaphylaxis : a stepwise diagnosis].

Gaillard J, Borgeat-Kaeser A, Buss G, Spertini F.

Rev Med Suisse. 2017 Apr 5;13(557):734-738. French.

PMID:
28722361
22.

Disponibilité de la désensibilisation en allergologie aujourd’hui : étape ou tournant historique ?

Harr T, Spertini F, Seebach J.

Rev Med Suisse. 2017 Apr 5;13(557):731-732. French. No abstract available.

PMID:
28722360
23.

Reactogenicity to major tuberculosis antigens absent in BCG is linked to improved protection against Mycobacterium tuberculosis.

Aguilo N, Gonzalo-Asensio J, Alvarez-Arguedas S, Marinova D, Gomez AB, Uranga S, Spallek R, Singh M, Audran R, Spertini F, Martin C.

Nat Commun. 2017 Jul 14;8:16085. doi: 10.1038/ncomms16085.

24.

[Hope for chronic inflammatory diseases : the anti-IL-6 receptor monoclonal antibody tocilizumab].

Spertini F.

Rev Med Suisse. 2017 Jan 11;13(544-545):20-22. Review. French.

PMID:
28703529
25.

[Innovations in the treatment of severe asthma].

Buss G, Spertini F.

Rev Med Suisse. 2017 Jan 11;13(544-545):18-19. Review. French.

PMID:
28703528
26.

Tocilizumab for giant cell arteritis with corticosteroid-resistant progressive anterior ischemic optic neuropathy.

Vionnet J, Buss G, Mayer C, Sokolov AA, Borruat FX, Spertini F.

Joint Bone Spine. 2017 Oct;84(5):615-619. doi: 10.1016/j.jbspin.2017.04.009. Epub 2017 May 9. Review.

PMID:
28499892
27.

Human Bronchial Epithelial Cells Induce CD141/CD123/DC-SIGN/FLT3 Monocytes That Promote Allogeneic Th17 Differentiation.

Gazdhar A, Blank F, Cesson V, Lovis A, Aubert JD, Lazor R, Spertini F, Wilson A, Hostettler K, Nicod LP, Obregon C.

Front Immunol. 2017 Apr 25;8:447. doi: 10.3389/fimmu.2017.00447. eCollection 2017.

28.

Elevated serum levels of free interleukin-18 in adult-onset Still's disease.

Girard C, Rech J, Brown M, Allali D, Roux-Lombard P, Spertini F, Schiffrin EJ, Schett G, Manger B, Bas S, Del Val G, Gabay C.

Rheumatology (Oxford). 2016 Dec;55(12):2237-2247. Epub 2016 Sep 10.

PMID:
27616144
29.

Biases affecting injected doses of an experimental drug during clinical trials.

Perrottet N, Brunner-Ferber F, Grouzmann E, Spertini F, Biollaz J, Buclin T, Widmer N.

Trials. 2016 Jul 16;17(1):321. doi: 10.1186/s13063-016-1463-5.

30.

Efficacy of 2 months of allergen-specific immunotherapy with Bet v 1-derived contiguous overlapping peptides in patients with allergic rhinoconjunctivitis: Results of a phase IIb study.

Spertini F, DellaCorte G, Kettner A, de Blay F, Jacobsen L, Jutel M, Worm M, Charlon V, Reymond C.

J Allergy Clin Immunol. 2016 Jul;138(1):162-8. doi: 10.1016/j.jaci.2016.02.044. Epub 2016 May 6.

PMID:
27373329
31.

Interferon α kinoid induces neutralizing anti-interferon α antibodies that decrease the expression of interferon-induced and B cell activation associated transcripts: analysis of extended follow-up data from the interferon α kinoid phase I/II study.

Ducreux J, Houssiau FA, Vandepapelière P, Jorgensen C, Lazaro E, Spertini F, Colaone F, Roucairol C, Laborie M, Croughs T, Grouard-Vogel G, Lauwerys BR.

Rheumatology (Oxford). 2016 Oct;55(10):1901-5. doi: 10.1093/rheumatology/kew262. Epub 2016 Jun 28.

32.

MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis.

Bousquet J, Schünemann HJ, Hellings PW, Arnavielhe S, Bachert C, Bedbrook A, Bergmann KC, Bosnic-Anticevich S, Brozek J, Calderon M, Canonica GW, Casale TB, Chavannes NH, Cox L, Chrystyn H, Cruz AA, Dahl R, De Carlo G, Demoly P, Devillier P, Dray G, Fletcher M, Fokkens WJ, Fonseca J, Gonzalez-Diaz SN, Grouse L, Keil T, Kuna P, Larenas-Linnemann D, Lodrup Carlsen KC, Meltzer EO, Mullol J, Muraro A, Naclerio RN, Palkonen S, Papadopoulos NG, Passalacqua G, Price D, Ryan D, Samolinski B, Scadding GK, Sheikh A, Spertini F, Valiulis A, Valovirta E, Walker S, Wickman M, Yorgancioglu A, Haahtela T, Zuberbier T; MASK study group*.

J Allergy Clin Immunol. 2016 Aug;138(2):367-374.e2. doi: 10.1016/j.jaci.2016.03.025. Epub 2016 Apr 23. Review.

33.

[If you go looking for trouble you'll find it. Urticarial reactions to insects of our local areas].

Maitre S, Kaeser A, Di Lucca J, Spertini F, Ribi C.

Rev Med Suisse. 2016 Apr 6;12(513):691-7. French.

PMID:
27197324
34.

[Food allergy in children: a diagnostic challenge].

Roethlisberger S, Spertini F.

Rev Med Suisse. 2016 Apr 6;12(513):677-82. French.

PMID:
27197322
35.

Maladies certes rares ... mais le devoir de les évoquer....

Spertini F, Seebach JD.

Rev Med Suisse. 2016 Apr 6;12(513):675. French. No abstract available.

PMID:
27197321
36.

Switching Patients to Home-Based Subcutaneous Immunoglobulin: an Economic Evaluation of an Interprofessional Drug Therapy Management Program.

Perraudin C, Bourdin A, Spertini F, Berger J, Bugnon O.

J Clin Immunol. 2016 Jul;36(5):502-10. doi: 10.1007/s10875-016-0288-z. Epub 2016 May 2.

PMID:
27139500
37.

Immunogenicity of dimorphic and C-terminal fragments of Plasmodium falciparum MSP2 formulated with different adjuvants in mice.

Balam S, Jafarshad A, Servis C, Frank G, Reed S, Pink R, Druilhe P, Spertini F, Corradin G.

Vaccine. 2016 Mar 18;34(13):1566-1574. doi: 10.1016/j.vaccine.2016.02.013. Epub 2016 Feb 11.

PMID:
26874325
38.

Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study.

De Santis O, Audran R, Pothin E, Warpelin-Decrausaz L, Vallotton L, Wuerzner G, Cochet C, Estoppey D, Steiner-Monard V, Lonchampt S, Thierry AC, Mayor C, Bailer RT, Mbaya OT, Zhou Y, Ploquin A, Sullivan NJ, Graham BS, Roman F, De Ryck I, Ballou WR, Kieny MP, Moorthy V, Spertini F, Genton B.

Lancet Infect Dis. 2016 Mar;16(3):311-20. doi: 10.1016/S1473-3099(15)00486-7. Epub 2015 Dec 23.

39.

Safety of human immunisation with a live-attenuated Mycobacterium tuberculosis vaccine: a randomised, double-blind, controlled phase I trial.

Spertini F, Audran R, Chakour R, Karoui O, Steiner-Monard V, Thierry AC, Mayor CE, Rettby N, Jaton K, Vallotton L, Lazor-Blanchet C, Doce J, Puentes E, Marinova D, Aguilo N, Martin C.

Lancet Respir Med. 2015 Dec;3(12):953-62. doi: 10.1016/S2213-2600(15)00435-X. Epub 2015 Nov 17.

PMID:
26598141
40.

[Subcutaneous immunoglobulin and support program: what level of interest of patients?].

Bourdin A, Berger J, Früh A, Spertini F, Bugnon O.

Rev Med Suisse. 2015 Apr 8;11(469):831-5. French.

PMID:
26040165
41.

["To case report or not", the interest of studies n=1].

Spertini F, Seebach JD.

Rev Med Suisse. 2015 Apr 8;11(469):799-800. French. No abstract available.

PMID:
26040159
42.

EAACI IG Biologicals task force paper on the use of biologic agents in allergic disorders.

Boyman O, Kaegi C, Akdis M, Bavbek S, Bossios A, Chatzipetrou A, Eiwegger T, Firinu D, Harr T, Knol E, Matucci A, Palomares O, Schmidt-Weber C, Simon HU, Steiner UC, Vultaggio A, Akdis CA, Spertini F.

Allergy. 2015 Jul;70(7):727-54. doi: 10.1111/all.12616. Epub 2015 Apr 24. Review.

PMID:
25819018
43.

[Allergic rhinitis: still insufficiently responsive to therapies].

Spertini F.

Rev Med Suisse. 2015 Jan 14;11(456-457):15-9. French.

PMID:
25799645
44.

Plasmodium falciparum merozoite surface protein 2: epitope mapping and fine specificity of human antibody response against non-polymorphic domains.

Balam S, Olugbile S, Servis C, Diakité M, D'Alessandro A, Frank G, Moret R, Nebie I, Tanner M, Felger I, Smith T, Kajava AV, Spertini F, Corradin G.

Malar J. 2014 Dec 19;13:510. doi: 10.1186/1475-2875-13-510.

45.

The Swiss Systemic lupus erythematosus Cohort Study (SSCS) - cross-sectional analysis of clinical characteristics and treatments across different medical disciplines in Switzerland.

Ribi C, Trendelenburg M, Gayet-Ageron A, Cohen C, Dayer E, Eisenberger U, Hauser T, Hunziker T, Leimgruber A, Lindner G, Koenig K, Otto P, Spertini F, Stoll T, Von Kempis J, Chizzolini C; Swiss Systemic Lupus Erythematosus Cohort Study Group.

Swiss Med Wkly. 2014 Aug 7;144:w13990. doi: 10.4414/smw.2014.13990. eCollection 2014.

46.

Adverse reactions to biologic agents and their medical management.

Boyman O, Comte D, Spertini F.

Nat Rev Rheumatol. 2014 Oct;10(10):612-27. doi: 10.1038/nrrheum.2014.123. Epub 2014 Aug 12. Review.

PMID:
25112605
47.

Safety and immunogenicity of the M72/AS01 candidate tuberculosis vaccine in HIV-infected adults on combination antiretroviral therapy: a phase I/II, randomized trial.

Thacher EG, Cavassini M, Audran R, Thierry AC, Bollaerts A, Cohen J, Demoitié MA, Ejigu D, Mettens P, Moris P, Ofori-Anyinam O, Spertini F.

AIDS. 2014 Jul 31;28(12):1769-81. doi: 10.1097/QAD.0000000000000343.

PMID:
24911353
48.

[Shingles vaccine: which recommendations in 2014?].

Vionnet J, Hart K, Spertini F.

Rev Med Suisse. 2014 Apr 16;10(426):869-72, 874-5. French.

PMID:
24834646
49.

[Food allergy or food intolerance?].

Maître S, Maniu CM, Buss G, Maillard MH, Spertini F, Ribi C.

Rev Med Suisse. 2014 Apr 16;10(426):846-50, 852-3. French.

PMID:
24834642
50.

[Rumbling, spasms and diarrhea: do not throw more!].

Spertini F, Seebach JD.

Rev Med Suisse. 2014 Apr 16;10(426):843-4. French. No abstract available.

PMID:
24834641

Supplemental Content

Loading ...
Support Center